NCT05620732

Efficacy and Safety of Claudin18.2CAR-T in Advanced Pancreatic Cancer and Gastric Carcinoma

Study Summary

The efficacy of advanced pancreatic cancer and gastric cancer needs to be further improved. Claudin is a kind of integrin membrane protein in the tight junction between epithelium and endothelium, which is highly expressed in gastric cancer and pancreatic cancer. Preclinical studies suggest that Claudin18.2CAR-T can effectively improve the remission rate of patients with advanced solid tumors.

Want to learn more about this trial?

Request More Info

Interventions

Claudin18.2 CAR-T cellsBIOLOGICAL
patients treated with Claudin18.2 CAR-T cells

Study Locations

FacilityCityStateCountry
Li YuShenzhenGuangdongChina

Official Trial Information

View on ClinicalTrials.gov

Data sourced from ClinicalTrials.gov. Last updated: April 14, 2026